Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors

Biomedical Chromatography

Volumn 27, Issue 10, 2013, Pages 1259-1272

  Mullangi, Ramesh ^a   Srinivas, Nuggehally R ^b  

^a JUBILANT BIOSYS LTD   (India)

^b Presidency Group of Institutions   (India)

Author keywords

Anacetrapib; Bioanalysis; Cardiovascular; CETP; Dalcetrapib; Torcetrapib

Indexed keywords

METABOLITES; PROTEINS; RISK ASSESSMENT;

ANACETRAPIB; BIOANALYSIS; CARDIOVASCULAR; CHOLESTERYL ESTER TRANSFER PROTEINS; CHOLETERYL ESTER TRANSFER PROTEIN; CLINICAL INVESTIGATION; DALCETRAPIB; PROTEIN INHIBITORS; TORCETRAPIB; TRANSFER PROTEIN;

ESTERS;

AGLYCONE; ANACETRAPIB; DALCETRAPIB; EVACETRAPIB; TORCETRAPIB;

ARTICLE; CHEMICAL STRUCTURE; CHIRALITY; CONJUGATE; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLITE; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE;

ANIMALIA;

EID: 84883559122     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2907     Document Type: Article

References (21)

1. Barter PJ and Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research 2012; 53: 1755-1766.
2. Bochem AE, Kuivenhoven JA and Stroes ES. The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. Current Pharmaceutical Design 2013 (in press).
3. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J and Obach RS. Pharmacokinetics, metabolism and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metabolism and Disposition 2008; 36: 2185-2198.
4. Goldberg AS and Hegele RA. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Design, Development and Therapy 2012; 6: 251-259.
5. Heinig K, Bucheli F, Kuhlmann O, Zell M, Pahler A, Zwanziger E, Gross G, Tardio J, Ishikawa T and Yamashita T. Determination of dalcetrapib by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2012; 66: 314-324.
6. Hewing B and Fisher EA. Rationale for cholesteryl ester transfer protein inhibition. Current Opinion in Lipidology 2012; 23: 372-376.
7. Joy T and Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Current Opinion in Cardiology 2009; 24: 364-371.
8. Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K and Wagner JA. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. British Journal of Pharmacology 2009; 68: 535-545.
9. Kumar S, Tan EY, Hartmann G, Biddle Z, Bergman AJ, Dru J, Ho JZ, Jones AN, Staskiewicz SJ, Braun MP, Karanam B, Dean DC, Gendrano IN, Graves MW, Wagner JA and Krishna R. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metabolism and Disposition 2010; 38: 474-483.
10. Luscher TF, von Eckardstein A and Simic B. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Current Vascular Pharmacology 2012; 10: 720-724.
11. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M and Dalvie D. Metabolism, pharmacokinetics and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metabolism and Disposition 2008; 36: 2064-2079.
12. Ramesh M, Trivedi RK and Srinivas NR. Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral technologies. Bioanalysis 2009; 1: 619-628.
13. Seiwert B and Karst U. Simultaneous LC/MS/MS determination of thiols and disulfides in urine samples based on differential labeling with ferrocene-based maleimides. Analytical Chemistry 2007; 79: 7131-7138.
14. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vascular Health and Risk Management 2012; 8: 323-331.
15. Srinivasan K, Nouri P and Kavetskaia O. Challenges in the indirect quantitation of acyl-glucuronide metabolites of a cardiovascular drug from complex biological mixtures in the absence of reference standards. Biomedical Chromatography 2010; 24: 759-767.
16. Tan EY, Hartmann G, Chen Q, Pereira A, Bradley S, Doss G, Zhang AS, Ho JZ, Braun MP, Dean DC, Tang W and Kumar S. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metabolism and Disposition 2010; 38: 459-473.
17. Toyo'oka T. Recent advances in separation and detection methods for thiol compounds in biological samples. Journal of Chromatography B 2009; 877: 3318-3330.
18. Trivedi RK, Dubey PK, Mullangi R and Srinivas SR. Development and validation of enantioselective HPLC-UV method using Chiralpak AD-H to quantify (+)- and (-)-torcetrapib enantiomers in hamster plasma - application to a pharmacokinetic study. Journal of Chromatography B 2007a; 857: 224-230.
19. Trivedi RK, Layek B, Kumar TS, Vittal S, Ganneboina R, Dubey PK, Mullangi R and Srinivas NR. Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal phase liquid chromatography and detection by atmospheric pressure chemical ionization tandem mass spectrometry. Journal of Chromatography B 2007b; 860: 227-234.
20. Trivedi RK, Dubey PK, Mullangi R and Srinivas NR. Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma. Biomedical Chromatography 2008; 22: 316-326.
21. Zhao L, Jin W, Rader D, Packard C and Feuerstein GA. Translational Medicine perspective of the development of torcetrapib: does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Biochemical Pharmacology 2009; 78: 315-325.